

Thursday, September 4, 2003

COMPANY PRESS RELEASE

Benefits of Transgenomic's WAVE[®] System Reviewed at Colorectal Cancer Meeting

Advancing the Epidemiologic Research Programs for The National Cancer Institute's Colon Cancer Family Registry

CLEVELAND, Sept. 4 / -- Transgenomic Inc. ([Nasdaq: T BIO](#)) announced today that the application of its WAVE System for DNA analysis will be discussed at the Fourth Joint Meeting of the Leeds Castle Polyposis Group and the International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer. This meeting is jointly sponsored by the Cleveland Clinic Foundation and is being held in Cleveland Sept. 2 through Sept. 6.

In a presentation to be given at this meeting, Robert Haile, Ph.D., professor and director of the Genetic Epidemiology Program, Department of Preventive Medicine at the University of Southern California's Keck School of Medicine, will discuss use of the WAVE System for detection of genetic mutations in individuals with hereditary forms of colorectal cancer. Dr. Haile is a principal investigator affiliated with the Colon Cancer Family Registry (the Colon CFR), a National Cancer Institute-funded international consortium of six research institutions. These centers and their collaborators are engaged in a cooperative effort to collect pedigree information, epidemiological data and related biological specimens from patients with a family history of colon cancer in order to provide a resource for epidemiologic and translational research. According to Dr. Haile, "An important goal of the Colon CFR is to test for mutations in the MSH2 and MLH1 genes in over 2,000 subjects with colorectal cancer. Most centers in the Colon CFR decided to use DHPLC and the WAVE System from Transgenomic because this technology provides us with a cost-effective, easy-to-use, robust and highly sensitive technique for mutation detection." He continued, "In addition, we like the fact that the WAVE System may be used for other research projects that we plan, including DNA or RNA sizing and quantitation, post-PCR fragment purification and collection, and genotyping using primer extension methods or microsatellite DNA analysis."

Collin D'Silva, Transgenomic's CEO, stated, "Several WAVE Systems have been recently purchased by CFR centers in addition to existing systems at several of these sites. We believe our WAVE technology is ideal for the analysis of genes such as MSH2 and MLH1, which are characterized by hundreds of different mutations in populations that have been studied to date. The WAVE System offers a time- and cost-effective means to scan genes of interest for almost all relevant mutations, eliminating the need to design and optimize specific probe- or primer-based tests for each individual mutation." In addition to these recent CFR center installations, the WAVE System is in use for colorectal cancer studies at several clinical labs around the world.

Transgenomic is also launching at the Cleveland meeting a complete operation package that includes a version of its WAVE System 3500HT specially configured to streamline research on the genetic basis of colorectal cancer. The company is hosting free web-based seminar sessions in September that focus on use of the WAVE System to scan for mutations associated with colorectal cancer. Further details are available at <http://transgenomicevents.webex.com>.

About Transgenomic

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry for the synthesis, separation, analysis and purification of nucleic acids and a wide variety of nucleic acid-based specialty chemicals. Transgenomic's biosystems segment offers its WAVE Systems and associated consumables. These systems are specifically designed for use in genetic variation detection and single- and double-strand DNA/RNA analysis and purification. These systems

have been shown by our customers to have broad application in genetic research and molecular biology. To date there have been approximately one thousand systems installed in over 30 countries around the world.

Through its nucleic acids business segment, Transgenomic provides specialty chemicals, including advanced nucleic acid building blocks and associated reagents, which are used by our customers in applications such as genetic diagnostics and therapeutics. Manufacturing operations include a cGMP facility for the synthesis of oligonucleotides.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's Web site at www.transgenomic.com.

Forward-Looking Statement

Certain statements in this press release constitute "forward-looking statements" of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements include, but are not limited to, those with respect to suitability of WAVE technology for the analysis of particular genes associated with colorectal cancer. The known risks, uncertainties and other factors affecting these forward-looking statements are described from time to time in Transgenomic's reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward-looking statements, unless required by law.

For confirmation of release or further information, please contact:

Mitchell L. Murphy
Transgenomic Inc.
402-452-5418
mmurphy@transgenomic.com

Robert J. Pogulis, Ph.D.
Transgenomic Inc.
845-782-9617
rpogulis@transgenomic.com